Jefferies Financial Group Boosts Stake in Supernus Pharmaceuticals

Institutional investor increases ownership in specialty pharmaceutical company by 62% in Q3

Mar. 11, 2026 at 10:04am

Got story updates? Submit your updates here. ›

Jefferies Financial Group Inc. increased its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 62.0% in the third quarter, according to a recent 13F filing with the Securities & Exchange Commission. The institutional investor now owns 86,179 shares of the specialty pharmaceutical company's stock, worth $4,118,000 at the end of the quarter.

Why it matters

This transaction highlights the growing institutional interest in Supernus Pharmaceuticals, a company focused on developing central nervous system therapies. The 62% increase in Jefferies' stake suggests confidence in the company's product portfolio and future growth potential.

The details

According to the 13F filing, Jefferies Financial Group purchased an additional 32,979 shares of Supernus Pharmaceuticals during the third quarter, bringing its total ownership to 86,179 shares. This represents a 0.15% stake in the specialty pharmaceutical company.

  • Jefferies Financial Group increased its stake in Supernus Pharmaceuticals in the third quarter of 2026.

The players

Jefferies Financial Group Inc.

An American global investment banking and securities firm.

Supernus Pharmaceuticals, Inc.

A specialty pharmaceutical company focused on developing and commercializing central nervous system therapies.

Got photos? Submit your photos here. ›

The takeaway

The increased stake by Jefferies Financial Group in Supernus Pharmaceuticals suggests growing institutional confidence in the company's product pipeline and future growth prospects within the specialty pharmaceutical industry.